Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of a Novel Split Enzyme Diagnostic Platform for Use at the Point of Care

Award Number: R00EB034778
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2024
PERIOD OF PERFORMANCE END DATE: 08/31/2027

Group Awards By:

View Award Description

Development of a Novel Split Enzyme Diagnostic Platform for Use at the Point of Care - PROJECT SUMMARY Rapid, inexpensive detection of biomarkers at the point of care is vital for many clinical purposes. However, limitations in current detection platforms have prevented the sensitive detection of many protein and small molecule biomarkers, forcing clinicians to rely on either potentially inaccurate empirical diagnosis or expensive lab tests to make critical treatment decisions. Sensitive detection of nucleic acid targets has been readily achieved by exploiting Watson-Crick base pairing to amplify signals (e.g., PCR), but there has been a lack of innovation for detection of low concentration antigens and small molecules at the point of care. Nature, on the other hand, has evolved intricate mechanisms for rapidly amplifying protein signals in vivo via post-translational modification and protein-based signaling networks that could be adapted for biomarker detection. Towards the goal of developing novel, rapid, ultrasensitive diagnostics, the central hypothesis of this project is that in vitro, protein-based signaling networks incorporating self-amplifying motifs can detect clinical biomarkers. Specifically, we plan to incorporate three mechanisms of protein signaling networks with potential for diagnostics: split enzyme reconstitution, autocatalytic positive feedback loops, and small molecule biosensors. We have previously demonstrated the in vitro use of split adenylate cyclase for small molecule detection via the simultaneous binding of two proteins (i.e. a sandwich assay in solution), bringing two halves of adenylate cyclase together and producing cAMP. Aim 1 (K99) will incorporate binding domains for detection of clinically relevant biomarker targets and investigate detection in human sample matrices. We will test different binding domains fused to split adenylate cyclase fragments to detect Hepatitis C Core Antigen (HCVcAg). Towards the development of a point-of-care diagnostic, Aim 2 (K99) will optimize reaction components for lyophilization and long-term storage and develop a hand-held point-of-care reader to detect the shift in fluorescence produced by the FRET-based cAMP biosensor. Lab-bench validation of all components will be performed using HCVcAg spiked into commercially purchased pooled blood samples. Aim 3 (R00) will investigate the use of split adenylate cyclase and cAMP receptor protein to create an autocatalytic feedback loop in vitro. This work would result in the first known in vitro protein signaling network with bistable switch-like sensing, a significant advancement for the diagnostics field. If successful, this system would be broadly applicable for protein and small molecule detection and could be used to detect a wide range of target analytes with known binding domains. As such, future work includes the incorporation of binding domains to detect other high value protein and small molecule analytes currently unable to be rapidly detected at the point of care and the clinical translation of the described diagnostic device with pilot clinical trials in collaboration with both domestic and foreign clinical partners.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $249,000 )
2025	2025	CLEMSON UNIVERSITY	201 SIKES HALL	CLEMSON	SC	29634	PICKENS	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	3	8/7/2025	NON-COMPETING CONTINUATION	$249,000
														Subtotal = $249,000

Issue Date FY: 2024 ( Subtotal = $249,000 )
2024	2024	CLEMSON UNIVERSITY	201 SIKES HALL	CLEMSON	SC	29634	PICKENS	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	2	9/13/2024	EXTENSION WITH OR WITHOUT FUNDS	$249,000
														Subtotal = $249,000

Grand Total All Awards = $498,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a Novel Split Enzyme Diagnostic Platform for Use at the Point of Care

Award Number: R00EB034778

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2024

PERIOD OF PERFORMANCE END DATE: 08/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer